Download Second Generation Patents in Pharmaceutical Innovation by Hyewon Ahn PDF

By Hyewon Ahn

The advance of latest medicines and enhancements thereof are the most important to make sure endured profits in healthiness. the improvement method is lengthy and dear, regularly to supply the data that meets excessive regulatory necessities. by contrast, imitation includes negligible expenditures and masses lowered hazards. this can be one of many purposes the pharmaceutical relies tremendously on patent safeguard. regardless of the prevailing patent process, even though, the variety of new drugs in keeping with 12 months has diminished, specifically over the past decade. compared, the variety of moment iteration patents and items has been tremendously elevated. The pharmaceutical is accused either one of neglecting its actual venture of offering new drugs, whereas producing moment iteration items, and of forestalling the access of generics. This dissertation reports even if the worries are justified, and, if this is the case, no matter if or how the patent process can increase the location that confronts pharmaceutical businesses and society. Dissertation. (Series: Munich highbrow estate legislation middle - MIPLC - Vol. 19)

Show description

Read or Download Second Generation Patents in Pharmaceutical Innovation PDF

Similar law books

An Introduction to the International Law of Armed Conflicts

This e-book presents a contemporary and simple creation to a department of foreign legislation continuously gaining in value in foreign lifestyles, particularly foreign humanitarian legislation (the legislation of armed conflict). it's built in a manner appropriate for self-study. The subject-matters are mentioned in self-contained chapters, permitting each one to be studied independently of the others.

Ethik und Recht - Die Ethisierung des Rechts/Ethics and Law - The Ethicalization of Law

Ziel des Buches ist es, das neue Phänomen der "Ethisierung des Rechts" interdisziplinär zu erfassen und damit das grundsätzliche Verhältnis von Ethik und Recht neu zu bestimmen. Dies geschieht zum einen durch die Untersuchung des theoretischen Fundaments der Beziehung von Recht und Ethik im 21. Jahrhundert.

Autorschaft Als Werkherrschaft in Digitaler Zeit: 15. Juli 2009 Symposium Frankfurt (German Edition)

Google digitalisiert Bucher, ohne deren Autoren zu fragen. Grossforschungseinrichtungen und zunehmend auch Universitaten drangen ihre Wissenschaftler, Publikationen moglichst schnell ins Netz zu stellen, fur jeden abrufbar. Dafur wird vorgebracht, dass es der Offentlichkeit nicht zuzumuten sei, fur Wissenschaft zweimal zu bezahlen - einmal auf der Produktionsseite durch Entlohnung und Forderung der Wissenschaftler und ein zweites Mal als Konsument der Verlagserzeugnisse.

Property and Human Rights in a Global Context

Estate as a human rights main issue is manifested via its incorporation in overseas tools and as an issue of the legislations via property-related instances thought of by way of foreign human rights organs. but, for the main half, the connection among estate and human rights has been mentioned in really superficial phrases, missing a transparent considerable connection or universal language.

Extra info for Second Generation Patents in Pharmaceutical Innovation

Example text

Htm#M (Last accessed on December 20, 2013); Pisano, 2006, 119 (noting “new molecular entities (NMEs)-both small molecules and biologics-”). 183 NIHCM, 2002, 4. int/ medicines/services/inn/en/ (Last accessed on December 20, 2013); this INN can be also called as a “generic name” that is contrasting to the “brand name,” however, in order to avoid any future confusion, this term is not used in this thesis. 185 Hansen/Hirsch, 1997, 324. 186 Wertheimer/Santella/Chaney, 17 J. Pharmaceut. Marketing Manage.

J. , 1427 (2008). 74 Methylenblau, 22 Reichsgericht in Zivilsachen 8 (holding “the product manufactured by means of the (protected) process does not fall outside of subject-matter of invention, and constitutes the end-point as characterized by patent law. ”). ). 76 Cohen/Nelson/Walsh, 2000, 10. 77 Grubb/Thomsen, 2010, 245. 78 TRIPS Art. 34 (Process Patents: Burden of Proof), In other words, the court would assume that it has been produced by the patented process unless the alleged infringer would prove otherwise.

2. 185 A product resulting from this research is often derogatorily called a “me-too” product, because it follows the research prospects that others have already successfully identified. 186 These may be also NMEs, and they will be subject to all preclinical and clinical trials to prepare the data necessary to meet the regulatory requirements. , 9 Nat. Rev. Drug Discov. htm#M (Last accessed on December 20, 2013); Pisano, 2006, 119 (noting “new molecular entities (NMEs)-both small molecules and biologics-”).

Download PDF sample

Rated 4.57 of 5 – based on 47 votes
Posted in Law